TRIUMPH-1, -2, and -3 run for 80 weeks (16 weeks escalation + 64 weeks maintenance)
Estimates range from 1560% across sources depending on measurement method and whether resistance training was involved
In the IMPACT trial, pemvidutide achieved mean weight losses of 4.8% and 5.8% with 1.2 and 1.8 mg doses respectively at 24 weeks, compared to 0.5% with placebo, with weight loss curves showing no evidence of plateauing, suggesting continued benefit with longer treatment [49-51]
To investigate, the research team analyzed electronic health records from 606,434 U.S
The weight loss benefits of microdosing GLP-1 Research suggests that many dont need the higher doses of GLP-1 medications to see meaningful results
This strain has received particular attention in the GLP-1 context because it influences short-chain fatty acid production and may enhance endogenous GLP-1 production